Source: Annual Congress 2010 - COPD: phenotyping and monitoring
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Ward, M. Miller, R. Stockley (United Kingdom). Alpha-1 antitrypsin COPD phenotypes are clinically more valid when defined by LLN rather than percent of predicted. Eur Respir J 2010; 36: Suppl. 54, 1317

Member's Comments

No comment yet.

Related content which might interest you: The prognostic value of CT-based lung density histograms in patients with severe alpha-1 antitrypsin deficiency Source: Eur Respir J 2004; 24: Suppl. 48, 296s Year: 2004 COPD in individuals with the PiMZ alpha-1 antitrypsin genotype Source: Eur Respir Rev, 26 (146) 170068; 10.1183/16000617.0068-2017 Year: 2017 Alpha-1 antitrypsin deficiency in patients with COPD/emphysema, bronchiectasis and asthma Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases Year: 2020 The prevalence of patients with normal post-bronchodilator spirometry that fulfil the criteria for GOLD mild COPD using ECCS predicted equations Source: International Congress 2019 – Respiratory function assessment in disease Year: 2019 Alpha-1 antitrypsin (A1-PI) treatment slows emphysema progression independent of baseline FEV1 Source: International Congress 2017 – New frontiers in home care management of chronic lung diseases Year: 2017 Alpha-1 antitrypsin deficiency in COPD patients: Time to count it in! Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Comparison of exercise training responses in COPD patients with and without Alpha-1 antitrypsin deficiency Source: International Congress 2018 – Latest advances in pulmonary rehabilitation assessment and content Year: 2018 Prevalence of alpha-1 antitrypsin deficiency (AATD) and frequencies of alleles PI*S and PI*Z in patients with COPD in Brazil Source: Annual Congress 2013 –Assessing the prevalence of COPD in the general population Year: 2013 Patterns of exacerbations in alpha 1 antitrypsin deficiency (AATD) Source: International Congress 2015 – Connective tissue disorders Year: 2015 Clinical features of alpha one antitrypsin deficiency in COPD Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Functional alterations of small airways in patients with alpha-1 antitrypsin deficiency (AATD) in a longitudinal study Source: Eur Respir J 2005; 26: Suppl. 49, 361s Year: 2005 Performance of the BODE index in patients with ?1-antitrypsin deficiency-related COPD Source: Eur Respir J 2014; 44: 78-86 Year: 2014 Specific airway resistance as a marker of early disease in alpha-1 antitrypsin deficiency Source: International Congress 2015 – Lung function: exploring the boundaries of the respiratory system Year: 2015 Bronchiectasis but not emphysema is more prevalent in non-PiZ alpha-1 antitrypsin deficiency (AATD) COPD than in usual COPD Source: International Congress 2014 – Genetics and environmental factors underlying asthma and COPD Year: 2014 Alpha-1 antitrypsin deficiency severity and the risk of COVID-19 Source: Virtual Congress 2021 – Burden and epidemiology of COVID-19 Year: 2021 COPD and alpha-1 antitrypsin deficiency emphysema: characteristics and survival after Lung Transplantation Source: International Congress 2018 – Moving lung transplantation forward Year: 2018 The relationship of small airways disease to spirometry and emphysema in alpha-1 antitrypsin deficiency Source: International Congress 2014 – Monitoring airway diseases with lung function tests Year: 2014 Differences in training response between patients with alpha-1 antitrypsin deficiency and COPD patients Source: International Congress 2015 – Best abstracts in functional capacity in chronic lung diseases Year: 2015 The predictive values of bronchodilator reversibility indicators in asthmatic patients with non-obstructive patterns of spirometry Source: International Congress 2019 – Respiratory function assessment in disease Year: 2019